Biphasic insulin aspart 30 for the treatment of type 1 diabetes mellitus

Abstract

Background: Type 1 diabetes mellitus is associated with acute and long-term complications, to which pre- and postprandial hyperglycemia are independent contributors. The objective of this review was to evaluate evidence-based information using biphasic insulin aspart 30 in the treatment of type 1 diabetes mellitus. Methods: The study reviewed the Cochrane Database and scientific literature (PubMed) published until January 2008 using the words biphasic insulin aspart 30 insulin or premixed aspart insulin. Conclusions: Biphasic insulin aspart 30 is similar in efficacy to biphasic human insulin in improving hemoglobin A_1c levels, with the advantage of a better postprandial glucose profile. Expert opinion. There is evidence supporting the efficacy and safety of biphasic insulin aspart 30 insulin. However, the need for well-designed clinical trials aimed at understanding the potential differences in safety and efficacy between patients with type 1 and type 2 diabetes is crucial.

Keywords::

• biphasic insulin
• insulin aspart
• type 1 diabetes

Acknowledgments

This work was partially supported by funding from the National Center for Research Resources (grant nos RR0207887 and RR-00211), components of the National Institutes of Health, the Children's Foundation Research Center and the UT Lifestyle Diabetes and Obesity Center. The authors thank Andrea Patters for her editorial assistance.